<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04357509</url>
  </required_header>
  <id_info>
    <org_study_id>ScTIL210-002-2019</org_study_id>
    <nct_id>NCT04357509</nct_id>
  </id_info>
  <brief_title>The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma</brief_title>
  <official_title>An Open-lable,Single-arm,Single-dose Escalation and Multiple-dose Expansion Clinical Study of Cell Therapy to Observe and Evaluate the Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-lable, single-arm, single-dose escalation and multiple-dose expansion&#xD;
      clinical study of cell therapy to observe and evaluate the tolerance, pharmacokinetic&#xD;
      characteristics, safety and efficacy of ScTIL210（Super circulating tumor infiltrating&#xD;
      lymphocytes）in the treatment of Melanoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>24 weeks after the last cell transfusion</time_frame>
    <description>Including cases of CR and PR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DCR)</measure>
    <time_frame>24 weeks after the last cell transfusion</time_frame>
    <description>The number of cases with remission and stable lesions after treatment accounted for the total number of evaluable cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response(DOR)</measure>
    <time_frame>24 weeks after the last cell transfusion</time_frame>
    <description>Time from complete remission (CR) or partial remission (PR) to disease progression (PD), death or last tumor evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival(PFS)</measure>
    <time_frame>24 weeks after the last cell transfusion</time_frame>
    <description>From the beginning of cell therapy to the time of the first disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>24 weeks after the last cell transfusion</time_frame>
    <description>Time from cell reinfusion to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events(AEs)</measure>
    <time_frame>24 weeks after the last cell transfusion</time_frame>
    <description>According to National Cancer Institute Common Terminology Criteria for Adverse Events V5.0(CTCAE V5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of Lentivirus Copy Number</measure>
    <time_frame>24 weeks after the last cell transfusion</time_frame>
    <description>Dynamic changes of carrier gene copy number in peripheral blood</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>ScTIL210</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This trial is designed single arm. All the subjects enrolled will receive the experimental intervention, ScTIL210(Super circulating tumor infiltrating lymphocytes).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Super circulating tumor infiltrating lymphocytes(ScTIL)</intervention_name>
    <description>Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with &quot;enhanced receptor&quot; and &quot;superamplification factor&quot;. The obtained ScTIL is used for one-time intravenous infusion.</description>
    <arm_group_label>ScTIL210</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged between 18 and 70 years old (inclusive), regardless of gender.&#xD;
&#xD;
          2. Expected survival duration is greater than three months.&#xD;
&#xD;
          3. Patients with acral and mucosal melanoma confirmed by histology or cytology.&#xD;
&#xD;
          4. Disease progression after previous first-line system treatment or intolerance during&#xD;
             the treatment. Intolerance includes the following:&#xD;
&#xD;
               1. Incompetence of major organ function restoration of the subject as judged by the&#xD;
                  investigator.&#xD;
&#xD;
               2. The subjects experienced Grade 3 non-hematological toxicity or Grade 4&#xD;
                  hematological toxicity during treatment (Grade 3 thrombocytopenia).&#xD;
&#xD;
               3. The subjects refuse the optional first-line treatment.&#xD;
&#xD;
          5. Subjects voluntarily accept peripheral blood apheresis to obtain cells for cell&#xD;
             preparation. The proportion of peripheral blood PD1(programmed death 1)positive T&#xD;
             cells in total T cells is ≥18%. The proportion of peripheral blood PD1 positive T&#xD;
             cells in total T cells ratio is ≥12% for the subjects underwent PD1 monoclonal&#xD;
             antibody treatment before screening.&#xD;
&#xD;
          6. At least one measurable focal lesion (for efficacy assessment) has been detected by CT&#xD;
             or MRI as defined by RECIST v1.1. The measurable tumor lesion is defined as the&#xD;
             longest diameter ≥ 10mm and the short diameter of metastatic lymph nodes ≥ 15mm under&#xD;
             the condition that the scanning thickness does not exceed 5.0 mm;&#xD;
&#xD;
          7. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of&#xD;
             0 to 1.&#xD;
&#xD;
          8. No serious hematology, liver, and kidney dysfunction, and meet the following&#xD;
             laboratory test criteria:&#xD;
&#xD;
               1. Hematology: neutrophils is equal to or higher than 1.5×10^9/L, platelets is equal&#xD;
                  to or higher than 75×10^9/L, hemoglobin is equal to or higher than 90g/L; total&#xD;
                  lymphocytes is equal to or higher than 50% of the normal lower line;&#xD;
&#xD;
               2. Liver function: alanine aminotransferase (ALT) and aspartate aminotransferase&#xD;
                  (AST) are both eqal to or lower than 3 times the upper limit of normal (ULN) (if&#xD;
                  intrahepatic bile duct cancer exists, equal to lower than 5 times of ULN); total&#xD;
                  bilirubin (TBIL) is equal to or lower than 2 times of ULN;&#xD;
&#xD;
               3. Kidney function: creatinine (Cr) is equal to or lower than 1.5 times of ULN;&#xD;
&#xD;
               4. Coagulation function: prothrombin time (PT) is equal to or shorter than 1.5 times&#xD;
                  of ULN or activated partial prothrombin time (APTT) is equal to or shorter&#xD;
                  than1.5 times of ULN;&#xD;
&#xD;
               5. Urine protein concentration is equal to or lower than ≤ 1 +, no edema.&#xD;
&#xD;
               6. Albumin is equal to or higher than 3.0g/dl.&#xD;
&#xD;
          9. At the beginning of screening, the elution period upon completion of anticancer&#xD;
             chemotherapies and glucocorticoids (includes hydrocortisone, prednisone, prednisolone,&#xD;
             methylprednisolone) should be no shorter than 4 weeks; Palliative radiotherapy is&#xD;
             allowed, as long as the selected region(s) of the therapy is/are spatially distinct&#xD;
             from that correspondent to designated focus of lesion for efficacy assessment.&#xD;
&#xD;
         10. Male or fertile female subjects are required to take effective contraceptive measures&#xD;
             during the treatment as well as within 90 days upon completion of last therapeutic&#xD;
             cell reinfusion;&#xD;
&#xD;
         11. Full capability and commitment to abide by clinical research protocols and follow-up&#xD;
             procedures.&#xD;
&#xD;
         12. Subjects understand and are willing to abide by the study protocol and to participate&#xD;
             in the study by providing signed informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with Uveal/Ocular melanoma.&#xD;
&#xD;
          2. Subjects with symptomatic and/or untreated brain metastases (of any size and number).&#xD;
&#xD;
             a) Subjects with treated brain metastases can be considered for enrollment under the&#xD;
             condition that the disease must have remained stable for greater than 14 days before&#xD;
             starting screening.&#xD;
&#xD;
          3. Subjects with another primary malignancy within the past 3 years including breast&#xD;
             cancer, cervical cancer, bladder cancer in situ, and local prostate cancer);&#xD;
&#xD;
          4. Presence of any active autoimmune disease or a history of autoimmune disease (such as&#xD;
             the following, but not limited to: autoimmune hepatitis, interstitial pneumonia,&#xD;
             enteritis, vasculitis, nephritis; with exclusion of Asthma subjects who need&#xD;
             bronchodilators for medical intervention); however, the following patients are&#xD;
             allowed:&#xD;
&#xD;
               1. Vitiligo, psoriasis, hair loss without systemic treatment;&#xD;
&#xD;
               2. Well-controlled type 1 diabetes;&#xD;
&#xD;
               3. Hypothyroidism with replacement thyroid function.&#xD;
&#xD;
          5. Subjects receiving chronic systemic steroid treatment for any reason; with exception&#xD;
             of the low-dose glucocorticoid replacement therapy due to adrenal insufficiency.&#xD;
&#xD;
          6. Recipients of any organ transplant, including allogeneic stem cell transplants, with&#xD;
             exception of transplants requiring no immunosuppression (e.g, corneal transplants,&#xD;
             hair transplants).&#xD;
&#xD;
          7. Subjects with any forms of primary immunodeficiency (e.g, severe combined&#xD;
             immunodeficiency disease [SCID] and acquired immunodeficiency syndrome [AIDS])&#xD;
&#xD;
          8. Presence of major acute or chronic infections, including:&#xD;
&#xD;
               1. A known history of positive human immunodeficiency virus (HIV) or a known history&#xD;
                  of acquired immunodeficiency syndrome (not required for screening). If the&#xD;
                  investigator strongly suspects a HIV infection in a subject with no known medical&#xD;
                  history during the screening period, the subject should be tested for HIV in&#xD;
                  accordance to the local standard guidelines).&#xD;
&#xD;
               2. Active TB infection (evidences are: clinical symptoms, physical examination&#xD;
                  and/or medical imaging, and laboratory findings).&#xD;
&#xD;
               3. An active bacterial or fungal infection that requires systemic treatment.&#xD;
&#xD;
               4. Viral hepatitis, including hepatitis B and C, etc.&#xD;
&#xD;
               5. Subjects with syphilis virus positive&#xD;
&#xD;
          9. Acute exacerbation of chronic obstructive pulmonary disease , or other respiratory&#xD;
             diseases that requires hospitalization within 30 days prior to enrollment，or that&#xD;
             hinders study treatment.&#xD;
&#xD;
         10. Clinically significant cardiovascular or cerebrovascular diseases, such as:&#xD;
             cerebrovascular accident or stroke occured within6 months prior to enrollment),&#xD;
             myocardial infarction (occured within6 months prior to enrollment), unstable angina,&#xD;
             congestive heart failure (equal to or greater than Grade II of New York Heart&#xD;
             Association) or severe arrhythmia.&#xD;
&#xD;
         11. Subjects who are incapable tolerate or are allergic to contrast agents of CT scanning&#xD;
             or magnetic resonance imaging (MRI).&#xD;
&#xD;
         12. Subjects who participated in other clinical trials within 4 weeks prior to enrollment.&#xD;
&#xD;
         13. Pregnant or lactating women.&#xD;
&#xD;
         14. A history of alcoholic or drug abuse within 2 years (acknowledged via inquiries and&#xD;
             previous medical history) prior to enrollment.&#xD;
&#xD;
         15. Other severe acute or chronic diseases, or incompetency/have only restricted&#xD;
             competency for civil conduct.&#xD;
&#xD;
         16. Subjects or family members is/are incapable to understand the conditions and goals of&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xinan Sheng, Doctor</last_name>
    <phone>010-88196348</phone>
    <email>doctor_sheng@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Jun Guo</investigator_full_name>
    <investigator_title>Director of department of renal cancer and melanoma</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

